Recombinant factor IX (BeneFix®) by adjusted continuous infusion: A study of stability, sterility and clinical experience

Haemophilia

Volumn 7, Issue 2, 2001, Pages 140-145

  Chowdary, P ^a   Dasani, H ^a   Jones, J A H ^a   Loran, C M ^a   Eldridge, A ^a   Hughes, S ^a   Collins, P W ^a  

^a UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

Author keywords

Continuous infusion; Haemophilia B; Recombinant factor IX

Indexed keywords

HEPARIN; RECOMBINANT BLOOD CLOTTING FACTOR 9;

ADULT; AGED; ARTICLE; BACTERIUM CONTAMINATION; BLEEDING; CLINICAL ARTICLE; CLINICAL STUDY; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG STABILITY; DRUG STERILITY; DRUG STORAGE; ELECTIVE SURGERY; HEMOPHILIA B; HEMOSTASIS; HEPARINIZATION; HUMAN; IN VITRO STUDY; LICENSING; PRIORITY JOURNAL; TEMPERATURE; THROMBOPHLEBITIS; THROMBOSIS;

BLOOD LOSS, SURGICAL; CONSUMER PRODUCT SAFETY; DRUG EVALUATION; DRUG STABILITY; FACTOR IX; FEMALE; HEMOPHILIA B; HEMORRHAGE; HEPARIN; HUMANS; INFANT, NEWBORN; INFUSION PUMPS; MALE; METABOLIC CLEARANCE RATE; RECOMBINANT PROTEINS;

EID: 0035077498     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.2001.00494.x     Document Type: Article

References (9)

1. Continuous infusion of factor concentrates. Review of use in hemophilia A and demonstration of safety and efficacy in hemophilia B
2. Continuous infusion therapy in haemophilia
3. The feasibility of using concentrates containing factor IX for continuous infusion
4. Continuous infusion of FVIII and FIX concentrates: In vitro analysis of clinically relevant parameters
5. Safety and efficacy of high-purity concentrates in haemophiliac patients undergoing surgery by continuous infusion
6. Efficacy and safety of continuous infusion of Mononine during five surgical procedures in three hemophilic patients
7. Efficacy of a high purity, chemically treated and nanofiltered factor IX concentrate for continuous infusion in hemophilia patients undergoing surgery
8. Clinical evaluation of recombinant factor IX
9. The formulation of recombinant factor IX. Stability, robustness and convenience